Cathy Anne Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cathy Anne Pinto has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Tommi Tervonen
Kielo Research, Zug, Switzerland
3 shared publications Johanna Hyacinthe
Merck & Co., Inc., Kenilworth, USA
2 shared publications- Ulrik Kihlbom
Stockholm Centre for Health Care Ethics (CHE), LIME, Karolinska Institutet
2 shared publications - A. Brett Hauber
Pfizer Inc New York New York USA
1 shared publication Andrew Tershakovec
Merck & Co., Inc., Rahway, NJ, USA
1 shared publication- Anna Schultze
Department of Non‐communicable Disease Epidemiology London School of Hygiene & Tropical Medicine London UK
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1081-1088
Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm
Background: Randomized controlled trials are the gold standard for demonstrating treatment efficacy. When infeasible, external control arm (ECA) analysis is an effective way to interpret treatment arm results. We developed an ECA for a single-arm trial (LS-004) for a HIF-2α inhibitor (belzutifan) in 61 patients with VHL renal cell carcinoma (RCC) to help interpret results. With a median follow-up of 37.8 months in LS-004, the ORR was 64% (95% CI = 50.6 to 75.8); median time to surgery was not reached. Methods: The ECA was developed using natural history study data for VHL RCC patients undergoing active surveillance with ≤5 years of follow-up. Key LS-004 eligibility criteria were applied. Propensity score (PS) weighting was used to balance prognostic factors, with balance evaluated using standardized mean difference (SMD). PS adjusted point estimates and 95% CI for ORR and time to surgery (TTS) are presented. For the ECA, ORR was evaluated among patients with ≥3 scans to allow opportunity for a confirmed response. Results: The ECA included 244 patients (167 for ORR analysis). Prognostic factors were balanced with SMD < 0.1 for all covariates. PS adjusted ORR for LS-004 and ECA was 63.9% (95% CI = 51.9 to 76.0) and 1.5% (95% CI = 0.0 to 3.3), respectively. Median TTS was 51.3 (95% CI = 43.8 to not yet reached) months in ECA; not yet reached in LS-004. Conclusions: The belzutifan treatment effect is large compared with the ECA, supporting belzutifan efficacy in VHL RCC. Although residual confounding is possible, the large effect is unlikely due to chance.
- 8 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1081-1088
Open AccessBelzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm
Background: Randomized controlled trials are the gold standard for demonstrating treatment efficacy. When infeasible, external control arm (ECA) analysis is an effective way to interpret treatment arm results. We developed an ECA for a single-arm trial (LS-004) for a HIF-2α inhibitor (belzutifan) in 61 patients with VHL renal cell carcinoma (RCC) to help interpret results. With a median follow-up of 37.8 months in LS-004, the ORR was 64% (95% CI = 50.6 to 75.8); median time to surgery was not reached. Methods: The ECA was developed using natural history study data for VHL RCC patients undergoing active surveillance with ≤5 years of follow-up. Key LS-004 eligibility criteria were applied. Propensity score (PS) weighting was used to balance prognostic factors, with balance evaluated using standardized mean difference (SMD). PS adjusted point estimates and 95% CI for ORR and time to surgery (TTS) are presented. For the ECA, ORR was evaluated among patients with ≥3 scans to allow opportunity for a confirmed response. Results: The ECA included 244 patients (167 for ORR analysis). Prognostic factors were balanced with SMD < 0.1 for all covariates. PS adjusted ORR for LS-004 and ECA was 63.9% (95% CI = 51.9 to 76.0) and 1.5% (95% CI = 0.0 to 3.3), respectively. Median TTS was 51.3 (95% CI = 43.8 to not yet reached) months in ECA; not yet reached in LS-004. Conclusions: The belzutifan treatment effect is large compared with the ECA, supporting belzutifan efficacy in VHL RCC. Although residual confounding is possible, the large effect is unlikely due to chance.
- Open Access
- 12 December 2023
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 17 (2) , 147-159
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey
Objectives To understand industry practices and challenges when submitting patient experience data (PED) for regulatory decisions by the US Food and Drug Administration (FDA). Methods A two-part online survey related to collection, submission, and use of PED by FDA in regulatory decision-making (part 1) and a best-worst exercise for prioritizing potential PED initiatives (part 2) was completed by industry and contract research organization (CRO) members with ≥ 2 years of recent experience with patient-reported outcome (PRO), natural history study (NHS), or patient preference (PP) data; and direct experience with FDA filings including PED. Results A total of 50 eligible respondents (84% industry) completed part 1 of the survey, among which 46 completed part 2. Respondents mostly had PRO (86%) and PP (50%) experience. All indicated that FDA meetings should have a standing agenda item to discuss PED. Most (78%) reported meetings should occur before pivotal trials. A common challenge was justifying inclusion without knowing if and how data will be used. Most agreed that FDA and industry should co-develop the PED table in the FDA clinical review (74%), and the table should report reason(s) for not using PED (96%) in regulatory decision-making. Most important efforts to advance PED use in decision-making were a dedicated meeting pathway and expanded FDA guidance (51% each). Conclusions FDA has policy targets expanding PED use, but challenges remain regarding pathways for PED submission and transparency in regulatory decision-making. Alignment on the use of existing meeting opportunities to discuss PED, co-development of the PED table, and expanded guidance are encouraged.
- 12 December 2023
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 17 (2) , 147-159
Open AccessCurrent Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey
Objectives To understand industry practices and challenges when submitting patient experience data (PED) for regulatory decisions by the US Food and Drug Administration (FDA). Methods A two-part online survey related to collection, submission, and use of PED by FDA in regulatory decision-making (part 1) and a best-worst exercise for prioritizing potential PED initiatives (part 2) was completed by industry and contract research organization (CRO) members with ≥ 2 years of recent experience with patient-reported outcome (PRO), natural history study (NHS), or patient preference (PP) data; and direct experience with FDA filings including PED. Results A total of 50 eligible respondents (84% industry) completed part 1 of the survey, among which 46 completed part 2. Respondents mostly had PRO (86%) and PP (50%) experience. All indicated that FDA meetings should have a standing agenda item to discuss PED. Most (78%) reported meetings should occur before pivotal trials. A common challenge was justifying inclusion without knowing if and how data will be used. Most agreed that FDA and industry should co-develop the PED table in the FDA clinical review (74%), and the table should report reason(s) for not using PED (96%) in regulatory decision-making. Most important efforts to advance PED use in decision-making were a dedicated meeting pathway and expanded FDA guidance (51% each). Conclusions FDA has policy targets expanding PED use, but challenges remain regarding pathways for PED submission and transparency in regulatory decision-making. Alignment on the use of existing meeting opportunities to discuss PED, co-development of the PED table, and expanded guidance are encouraged.
- Open Access
- 17 July 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (10) , 103719
Regulatory benefit–risk assessment of oncology drugs: A systematic review of FDA and EMA approvals
- 17 July 2023
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (10) , 103719
Open AccessRegulatory benefit–risk assessment of oncology drugs: A systematic review of FDA and EMA approvals
- Open Access
- 16 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (10) , 1268-1277
Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma
Prior biomarker studies have mainly been restricted to advanced RCC patients treated in clinical trials or have had limited integration of immunotherapy features such as programmed death ligand (PD...
- 16 September 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (10) , 1268-1277
Open AccessMolecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma
Prior biomarker studies have mainly been restricted to advanced RCC patients treated in clinical trials or have had limited integration of immunotherapy features such as programmed death ligand (PD...
- 6 December 2021
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (4) , 201-214
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression
Background: Little is known regarding treatment patterns and overall survival (OS) for patients with advanced melanoma who progress after anti-PD-1 exposure. Methods: The Kaplan–Meier method was us...
- 6 December 2021
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (4) , 201-214
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression
Background: Little is known regarding treatment patterns and overall survival (OS) for patients with advanced melanoma who progress after anti-PD-1 exposure. Methods: The Kaplan–Meier method was us...
- Open Access
- 27 September 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 15 (2) , 255-266
Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment
Background Antithrombotic drugs are used as preventive treatment in patients with a prior myocardial infarction (MI) in both the acute and chronic phases of the disease. To support patient-centered benefit–risk assessment, it is important to understand the influence of disease stage on patient preferences. Objective The aim of this study was to examine patient preferences for antithrombotic treatments and whether they differ by MI disease phase. Methods A discrete-choice experiment was used to elicit preferences of adults in the acute (≤ 365 days before enrolment) or chronic phase (> 365 days before enrolment) of MI for key ischemic events (risk of cardiovascular [CV] death, non-fatal MI, and non-fatal ischemic stroke) and bleeding events (risk of non-fatal intracranial hemorrhage and non-fatal other severe bleeding). Preference data were analyzed using the multinomial logit model. Trade-offs between attributes were calculated as the maximum acceptable increase in the risk of CV death for a decrease in the risk of the other outcomes. To assess the potential effect of sociodemographic and clinical characteristics on patient preferences, subgroups were introduced as interaction terms in logit models. Results The evaluable population included 155 patients with MI in the acute phase of disease and 180 in the chronic phase. The overall population was 82% male, mean age was 64.2 ± 9.6 years, and 93% had not experienced bleeding events or key ischemic events other than MI. Patients valued reduction in the risk of non-fatal intracranial hemorrhage more than CV death (p < 0.01) and CV death more than non-fatal ischemic events (p < 0.01). Preferences were similar in the acute and chronic populations (p = 0.17). However, older patients valued reduction in risk of MI more than younger patients (p = 0.04), and patients with bleeding risk factors valued reduction in the risk of CV death (p = 0.01) and MI (p = 0.01) less than patients without bleeding risk factors. Also, patients who were at high risk of future ischemic events valued reduction of the risk of CV death less than those at low risk (p = 0.01). Conclusion Patient preferences for antithrombotic treatments were unaffected by disease stage but varied by bleeding risk and other factors. This heterogeneity in preferences is an important consideration because it can affect the benefit–risk balance and the acceptability of antithrombotic treatments to patients.
- 27 September 2021
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 15 (2) , 255-266
Open AccessComparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment
Background Antithrombotic drugs are used as preventive treatment in patients with a prior myocardial infarction (MI) in both the acute and chronic phases of the disease. To support patient-centered benefit–risk assessment, it is important to understand the influence of disease stage on patient preferences. Objective The aim of this study was to examine patient preferences for antithrombotic treatments and whether they differ by MI disease phase. Methods A discrete-choice experiment was used to elicit preferences of adults in the acute (≤ 365 days before enrolment) or chronic phase (> 365 days before enrolment) of MI for key ischemic events (risk of cardiovascular [CV] death, non-fatal MI, and non-fatal ischemic stroke) and bleeding events (risk of non-fatal intracranial hemorrhage and non-fatal other severe bleeding). Preference data were analyzed using the multinomial logit model. Trade-offs between attributes were calculated as the maximum acceptable increase in the risk of CV death for a decrease in the risk of the other outcomes. To assess the potential effect of sociodemographic and clinical characteristics on patient preferences, subgroups were introduced as interaction terms in logit models. Results The evaluable population included 155 patients with MI in the acute phase of disease and 180 in the chronic phase. The overall population was 82% male, mean age was 64.2 ± 9.6 years, and 93% had not experienced bleeding events or key ischemic events other than MI. Patients valued reduction in the risk of non-fatal intracranial hemorrhage more than CV death (p < 0.01) and CV death more than non-fatal ischemic events (p < 0.01). Preferences were similar in the acute and chronic populations (p = 0.17). However, older patients valued reduction in risk of MI more than younger patients (p = 0.04), and patients with bleeding risk factors valued reduction in the risk of CV death (p = 0.01) and MI (p = 0.01) less than patients without bleeding risk factors. Also, patients who were at high risk of future ischemic events valued reduction of the risk of CV death less than those at low risk (p = 0.01). Conclusion Patient preferences for antithrombotic treatments were unaffected by disease stage but varied by bleeding risk and other factors. This heterogeneity in preferences is an important consideration because it can affect the benefit–risk balance and the acceptability of antithrombotic treatments to patients.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 1331-1345
Taking into Account Patient Preferences: A Consensus Study on the Assessment of Psychological Dimensions Within Patient Preference Studies
Patient preferences are gaining recognition among key stakeholders involved in benefit-risk decision-making along the medical product lifecycle. However, one of the main challenges of integrating patient preferences in benefit-risk decision-making is understanding differences in patient preference, which may be attributable to clinical characteristics (eg age, medical history) or psychosocial factors. Measuring the latter may provide valuable information to decision-makers but there is limited guidance regarding which psychological dimensions may influence patient preferences and which psychological instruments should be considered for inclusion in patient preference studies. This paper aims to provide such guidance by advancing evidence and consensus-based recommendations and considerations. Findings of a recent systematic review on psychological constructs having an impact on patients’ preferences and health-related decisions were expanded with input from an expert group (n = 11). These data were then used as the basis for final recommendations developed through two rounds of formal evaluation via an online Delphi consensus process involving international experts in the field of psychology, medical decision-making, and risk communication (n = 27). Three classes of recommendations emerged. Eleven psychological constructs reached consensus to be recommended for inclusion with the strongest consensus existing for health literacy, numeracy, illness perception and treatment-related beliefs. We also proposed a set of descriptive and checklist criteria to appraise available psychological measures to assist researchers and other stakeholders in including psychological assessment when planning patient preference studies. These recommendations can guide researchers and other stakeholders when designing and interpreting patient preference studies with a potential high impact in clinical practice and medical product benefit-risk decision-making processes.
- 1 June 2021
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 1331-1345
Open AccessTaking into Account Patient Preferences: A Consensus Study on the Assessment of Psychological Dimensions Within Patient Preference Studies
Patient preferences are gaining recognition among key stakeholders involved in benefit-risk decision-making along the medical product lifecycle. However, one of the main challenges of integrating patient preferences in benefit-risk decision-making is understanding differences in patient preference, which may be attributable to clinical characteristics (eg age, medical history) or psychosocial factors. Measuring the latter may provide valuable information to decision-makers but there is limited guidance regarding which psychological dimensions may influence patient preferences and which psychological instruments should be considered for inclusion in patient preference studies. This paper aims to provide such guidance by advancing evidence and consensus-based recommendations and considerations. Findings of a recent systematic review on psychological constructs having an impact on patients’ preferences and health-related decisions were expanded with input from an expert group (n = 11). These data were then used as the basis for final recommendations developed through two rounds of formal evaluation via an online Delphi consensus process involving international experts in the field of psychology, medical decision-making, and risk communication (n = 27). Three classes of recommendations emerged. Eleven psychological constructs reached consensus to be recommended for inclusion with the strongest consensus existing for health literacy, numeracy, illness perception and treatment-related beliefs. We also proposed a set of descriptive and checklist criteria to appraise available psychological measures to assist researchers and other stakeholders in including psychological assessment when planning patient preference studies. These recommendations can guide researchers and other stakeholders when designing and interpreting patient preference studies with a potential high impact in clinical practice and medical product benefit-risk decision-making processes.
- Open Access
- 1 December 2020
- Published by Elsevier in Health Policy
- Vol. 124 (12) , 1325-1332
An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
- 1 December 2020
- Published by Elsevier in Health Policy
- Vol. 124 (12) , 1325-1332
Open AccessAn overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
- Open Access
- 28 February 2020
- Published by Morressier GmbH
A scoping review of scenario-based interactive tools used for patient preference construction and/or elicitation
Explore if scenario-based interactive tools (SBITs) that apply game mechanics have been used to construct or elicit patient preferences regarding treatment, assess how they may support the construction or elicitation of preferences, and formulate a set of design recommendations. A scoping literature review was performed. In November 2016 several electronic databases were searched
- 28 February 2020
- Published by Morressier GmbH
Open AccessA scoping review of scenario-based interactive tools used for patient preference construction and/or elicitation
Explore if scenario-based interactive tools (SBITs) that apply game mechanics have been used to construct or elicit patient preferences regarding treatment, assess how they may support the construction or elicitation of preferences, and formulate a set of design recommendations. A scoping literature review was performed. In November 2016 several electronic databases were searched
- 7 March 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 443-451
Personalized benefit‐risk assessments combining clinical trial and real‐world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy
Purpose: Quantitative benefit‐risk (B‐R) assessments are used to characterize treatment by combining key benefits and risks into a single metric but have historically been done for the “average” patient. Our aim was to conduct an individualized assessment for the oral antiplatelet vorapaxar by combining trial and real‐world data to further personalize the treatment profiles.Methods: Using linked UK health care databases, we developed risk prediction equations for key ischemic and bleeding events using Cox proportional hazards models. Trial hazard ratios, relative to placebo, were applied to baseline risk estimates to compute expected attributable risks, summed to derive a per‐patient net clinical benefit (NCB). High risk subgroups were defined a priori, and Gaussian mixture models (GMM) were fit to characterize the NCB distribution and identify subgroups with similar NCBs.Results: NCB was consistently positive for all subgroups, likely due to the outcome correlation, and would remain positive with a 12‐fold increase in bleeding risk. GMMs identified three distinct NCB subgroups. Compared with the middle/lower NCB subgroups, those with a higher NCB tended to be older, female, and have higher CV disease burden.Conclusions: Personalized B‐R assessments are feasible and clinically valuable and can be used to better predict who would benefit most from therapy.
- 7 March 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 443-451
Personalized benefit‐risk assessments combining clinical trial and real‐world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy
Purpose: Quantitative benefit‐risk (B‐R) assessments are used to characterize treatment by combining key benefits and risks into a single metric but have historically been done for the “average” patient. Our aim was to conduct an individualized assessment for the oral antiplatelet vorapaxar by combining trial and real‐world data to further personalize the treatment profiles.Methods: Using linked UK health care databases, we developed risk prediction equations for key ischemic and bleeding events using Cox proportional hazards models. Trial hazard ratios, relative to placebo, were applied to baseline risk estimates to compute expected attributable risks, summed to derive a per‐patient net clinical benefit (NCB). High risk subgroups were defined a priori, and Gaussian mixture models (GMM) were fit to characterize the NCB distribution and identify subgroups with similar NCBs.Results: NCB was consistently positive for all subgroups, likely due to the outcome correlation, and would remain positive with a 12‐fold increase in bleeding risk. GMMs identified three distinct NCB subgroups. Compared with the middle/lower NCB subgroups, those with a higher NCB tended to be older, female, and have higher CV disease burden.Conclusions: Personalized B‐R assessments are feasible and clinically valuable and can be used to better predict who would benefit most from therapy.